Who is sponsoring NCT02843321?

NCT02843321 is sponsored by University of Sydney.

What drugs are being tested in NCT02843321?

Interventions in NCT02843321: T-cell infusion, influenza vaccination.

What condition does NCT02843321 study?

NCT02843321 studies Complication of Transplant.

Is NCT02843321 still recruiting?

NCT02843321 is currently status unknown. Last updated 21 November 2016.

Last reviewed 2016-11-21 · How we verify

NCT02843321: CYNTAX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination to Enhance Infection-Specific Immune Reconstitution Post-Allogeneic Stem Cell Transplantation

Status unknown Phase 1 Last updated 21 November 2016

What this trial tests

Phase 1 trial testing T-cell infusion, influenza vaccination in Complication of Transplant in 12 participants. Status unknown.

Timeline

1 August 2012

Primary endpoint
1 December 2017

1 December 2017

Quick facts

Lead sponsor	University of Sydney
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 August 2012
Primary completion	1 December 2017
Estimated completion	1 December 2017
Sites	1 location across Australia

Drugs / interventions tested

T-cell infusion, influenza vaccination — full drug profile →

Conditions studied

Complication of Transplant — all drugs for Complication of Transplant →

Sponsor

University of Sydney

Who can join

Eligibility, any sex, with Complication of Transplant. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety of infection-specific T-cell infusion and vaccination
Time frame: 1 week
Presence of acute infusion related toxicities

Sponsor's own description

To assess the safety and biological efficacy of prophylactically administered donor-derived multi-infection specific cytotoxic T lymphocytes (CTLs) (targeting cytomegalovirus (CMV), Adenovirus (Adv), Epstein Barr virus (EBV), Varicella-Zoster virus (VZV), Influenza (Flu), BK virus (BKV), and Aspergillus (Asp)) combined with early immunisation with Influenza and VZV vaccines for the prevention of viral and fungal infection following allogeneic blood or marrow stem cell transplantation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunomodulation as Therapy for Fungal Infection: Are We Closer?
Sam QH, Yew WS, Seneviratne CJ, Chang MW, et al · · 2018 · cited 47× · PMID 30090091 · DOI 10.3389/fmicb.2018.01612
Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant.
Gottlieb DJ, Clancy LE, Withers B, McGuire HM, et al · · 2021 · cited 38× · PMID 33747509 · DOI 10.1002/cti2.1249

Verify or expand the search:

Other University of Sydney trials

Trials by the same sponsor.

NCT07173335 — Integrated Healthy Lifestyle and Pain Care for People With Musculoskeletal Conditions Living in Rural Areas. · NA · not yet recruiting
NCT06908486 — Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain · NA · recruiting
NCT06159660 — Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Function · not yet recruiting
NCT05568381 — Sleep Disturbance in MCI: A Study of a Cognitive Behavioural Therapy Digital Intervention · NA · completed
NCT05184790 — LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02843321 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sydney
Last refreshed: 21 November 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing